The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid
induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care
patients, however, is not known. Therefore, the researchers' goal is to investigate whether
naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients
already receiving prophylactic stool softeners and simulant laxatives through a double-blind,
randomized control trial.